The present disclosure relates to the field of Neisserial immunogenic compositions and vaccines, their manufacture and the use of such compositions in medicine. In particular the present invention relates to compositions and methods involving the factor H binding protein (fHbp) antigen. The present inventors have recognised that fHbp is poorly expressed in neisserial strains of ST269 clonal complex (a subset of strains which seems to be growing in terms of numbers of reported cases of disease attributed to it), and vaccines comprising fHbp may be made more effective against said strains by formulating the vaccine with a further antigen that can elicit protection against these strains.本発明はナイセリア菌の免疫原性組成物およびワクチン、それらの製造およびかかる組成物の医薬における使用の分野に関する。fHbpを誘導した髄膜炎菌に特異的であるfHbpに対する免疫応答の問題を克服するために、キメラfHbp(H因子結合タンパク質)タンパク質および前記タンパク質を含む組成物を記載した。【選択図】 なし
